within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XD06_Efaproxiral;

model Efaproxiral
  extends Pharmacolibrary.Drugs.ATC.L.L01XD06;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01XD06</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Efaproxiral (RSR13) is an allosteric effector of hemoglobin, designed to decrease hemoglobin oxygen affinity and thereby enhance tissue oxygenation. It was primarily investigated as a radiosensitizer for treatment of hypoxic tumors, especially in patients with brain metastases. Efaproxiral is not an approved drug and its clinical development has been discontinued.</p><h4>Pharmacokinetics</h4><p>Parameters derived from published phase I study in adult cancer patients (n=43), both sexes, median age around 57 years, after intravenous administration.</p><h4>References</h4><ol><li><p>Yi, R, et al., &amp; Morrissey, B (2014). Detection of efaproxiral (RSR13) and its metabolites in equine by liquid chromatography tandem mass spectrometry. <i>Journal of mass spectrometry : JMS</i> 49(1) 57–67. DOI:<a href=&quot;https://doi.org/10.1002/jms.3304&quot;>10.1002/jms.3304</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24446264/&quot;>https://pubmed.ncbi.nlm.nih.gov/24446264</a></p></li><li><p>Kavanagh, BD, et al., &amp; Gerber, MJ (2001). A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics. <i>International journal of radiation oncology, biology, physics</i> 49(4) 1133–1139. DOI:<a href=&quot;https://doi.org/10.1016/s0360-3016(00)01532-7&quot;>10.1016/s0360-3016(00)01532-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11240256/&quot;>https://pubmed.ncbi.nlm.nih.gov/11240256</a></p></li><li><p>Kleinberg, L, et al., &amp; Gerber, M (2002). Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 20(14) 3149–3155. DOI:<a href=&quot;https://doi.org/10.1200/JCO.2002.01.096&quot;>10.1200/JCO.2002.01.096</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12118029/&quot;>https://pubmed.ncbi.nlm.nih.gov/12118029</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Efaproxiral;
